 | |
| Company type | Public |
|---|---|
| |
| ISIN | INE044A01036 |
| Industry | Pharmaceuticals |
| Founded | 1983 |
| Founder | Dilip Shanghvi |
| Headquarters | , India |
Area served | Worldwide |
Key people | Dilip Shanghvi (MD) |
| Products | |
| Revenue |  ₹48,496 crore (US$5.8 billion) (FY24)[1] |
| ₹13,023 crore (US$1.6 billion) (FY24)[1] | |
| ₹9,576 crore (US$1.1 billion) (FY24)[1] | |
| Total assets | ₹85,462 crore (US$10 billion) (2024)[1] |
| Total equity | ₹67,105 crore (US$8.0 billion) (2024)[1] |
| Owner | Dilip Shanghvi family (54.48%) |
Number of employees | 41,000+ (2023) |
| Website | sunpharma |
| Footnotes / references [2][3] | |
Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals.
- ^ a b c d e "Board Meeting Outcome for Audited Financial Results And Dividend" (PDF). Sun Pharma. Retrieved 23 May 2024.
- ^ "Sun Pharmaceutical Announces Fourth Quarter and Fiscal Year 2018 Results" (PDF). mypharmaproducts.store. Sun Pharmaceutical. 4 February 2019. Archived (PDF) from the original on 10 May 2023. Retrieved 4 February 2019.
- ^ "Annual Report 2020-21" (PDF). Sun Pharmaceutical Industries. Archived (PDF) from the original on 3 November 2021. Retrieved 12 May 2022.